Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Comparison of Telogen Effluvium Incidence in Hospitalized and Outpatient Settings after Recovery from COVID-19.Iranian journal of medical sciences · 2024
   Article
2. Characteristics of hair loss after COVID-19: A systematic scoping review.Journal of cosmetic dermatology · 2022
   Article
3. Reply to early-onset effluvium secondary to COVID-19 and body hair effluvium.Journal of the American Academy of Dermatology · 2022
   Article

Corrections and comments

• Commented on by
  Reply to early-onset effluvium secondary to COVID-19 and body hair effluvium.2022
• Comment on
  Time of onset and duration of post-COVID-19 acute telogen effluvium.2021

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as